Evidence map›Paper›PMID 34599703›Full record

ArticleMolecular biology reports2021

Ribonucleotide reductase: In-vitro S-glutathionylation of R2 and p53R2 subunits of mammalian class I ribonucleotide reductase protein.

Ajanta Chatterji, Arne Holmgren, Rajib Sengupta

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Ajanta ChatterjiAmity Institute of Biotechnology Kolkata, Amity University Kolkata, Action Area II, Kadampukur Village, Rajarhat, Newtown, Kolkata, West Bengal, 700135, India.
Arne HolmgrenDivision of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
Rajib SenguptaAmity Institute of Biotechnology Kolkata, Amity University Kolkata, Action Area II, Kadampukur Village, Rajarhat, Newtown, Kolkata, West Bengal, 700135, India. rsengupta@kol.amity.edu.ORCID http://orcid.org/0000-0002-9665-8784
Karolinska Institutet · SE

Funding

Karolinska Institutet 2011FoBi0399Karolinska Institutet 2013fobi37677
6 · The paper itself

Abstract

Ribonucleotide reductases (RNR) catalyze the rate-limiting step in DNA synthesis during the S-phase of the cell cycle. Its constant activity in order to maintain dNTP homeostasis is a fascinating area of research and an attractive candidate for cancer research and antiviral drugs. Redox modification such as S-glutathionylation of the R1 subunit of mammalian RNR protein has been presumed to regulate the activity of RNR during catalytic cycles. Herein, we report S-glutathionylation of the R2 subunit. We have also shown Grx1 system can efficiently deglutathionylate the S-glutathionylated R2 subunit. Additionally, our data also showed for the very first time S-glutathionylation of mammalian p53R2 subunit that regulates DNA synthesis outside S-phase during DNA damage and repair. Taken together, these data will open new avenues for future research relating to exact physiological significance, target thiols, and/or overall RNR activity due to S-glutathionylation of R2 and p53R2 subunits and provide valuable insights for effective treatment regimes.

Indexed as

Cell Cycle ProteinsDNA ReplicationGlutathioneProtein SubunitsRibonucleotide ReductasesS PhaseAnimalsMiceCell Cycle ProteinsGlutathioneProtein SubunitsRibonucleotide ReductasesRrm2b protein, mouseGlutaredoxinGlutathioneRibonucleotide reductasesS-glutathionylation

Identifiers

PMID34599703
OpenAlexW3193875711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.